Search

for
Search:

Did you mean JAK1/2 inhibitor?

Glossary JAK1/2 inhibitor

medication that blocks enzymes involved in immune signaling

A JAK1/2 inhibitor is a type of medication that blocks the activity of Janus kinase 1 and 2 (JAK1 and JAK2), which are enzymes involved in the signaling pathways that regulate immune responses and inflammation. By inhibiting these enzymes, JAK1/2 inhibitors can help treat conditions like rheumatoid arthritis and certain types of alopecia, where the immune system mistakenly attacks the body's own tissues.

Related Terms

Janus Kinase 1

Research

5 / 842 results

research JAK inhibitors in dermatology: The promise of a new drug class

355 citations , January 2017 in “Journal of the American Academy of Dermatology”

This review reports no new results and highlights existing research suggesting JAK inhibitors may be effective in treating inflammatory skin conditions like alopecia areata, atopic dermatitis, psoriasis, and vitiligo.

research Emerging Topical and Systemic JAK Inhibitors in Dermatology

277 citations , December 2019 in “Frontiers in Immunology”

This review discusses the immunological basis and development of Janus kinase inhibitors for treating skin diseases and reports no new clinical findings.

research JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis

223 citations , September 2018 in “Rheumatology”

This review examines clinical data on the efficacy and safety of JAK inhibitors used for immune-mediated conditions beyond rheumatoid arthritis, highlighting their potential therapeutic roles in various inflammatory diseases.

research Under Development JAK Inhibitors for Dermatologic Diseases

14 citations , January 2020 in “Mediterranean Journal of Rheumatology”

This review discusses the development of Janus kinase inhibitors for dermatologic diseases and reports no new results; the authors note the need for further research on their efficacy and safety.

research 544 Alopecia areata lesions show significant changes in immune and keratin biomarkers that correlate with clinical improvement with oral Janus kinase inhibitors PF-06651600 (JAK3) and PF-06700841 (TYK2/JAK1)

5 citations , April 2019 in “Journal of Investigative Dermatology”

This study found that oral JAK3 and TYK2/JAK1 inhibitors improved clinical outcomes in alopecia areata patients by reducing immune responses and enhancing hair keratin expression, with stronger effects in those with shorter disease duration.

View more "jak1 inhibitor" in research →

Learn

— no results

Community Join

— no results

Experts

— no results

Try a deeper search in experts →

Clinics

— no results

Try a deeper search in clinics →